Clinical trials: multiple sclerosis
Stroke, Multiple Sclerosis
Exergames Balance Program in Neurorehabilitation
Exergames are games that require physical movements and are used with a therapeutic purpose, e.g. to improve strength, balance or flexibility.
- Conditions
- Stroke, Multiple Sclerosis, Balance Disorders
- Trial name
- NCT03993275
- Testing
- MindMotion GO
- Where
- Switzerland
- Volunteers
- 84 people
- Sponsor
- Klinik Valens
Multiple Sclerosis
Evaluation of the Effect of Mental Imagery Training Combined With Modified Constraint-Induced Movement Therapy in Individuals With Multiple Sclerosis
This study aims to investigate the effects of mental imagery training combined with modified constraint-induced movement therapy in individuals with multiple sclerosis.
- Trial name
- NCT07899411
- Testing
- odified Constraint-Induced Movement Therapy + Mental Imagery Training, Modified Constraint-Induced Movement Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Hacettepe University
Multiple Sclerosis, Spasticity
A Study of the Long-term Safety of Sativex Use
Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
- Conditions
- Multiple Sclerosis, Spasticity, Pain
- Trial name
- NCT01606137
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 507 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis
Multiple Sclerosis (MS) is a long-term disease that affects over 150,000 people in the UK. Starting treatment early is important for managing Multiple Sclerosis (MS).
- Trial name
- AssistMS (NCT07111637)
- Testing
- AI software
- Where
- United Kingdom
- Volunteers
- 1,336 people
- Sponsor
- Queen Mary University of London
Relapsing Multiple Sclerosis
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-302 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral…
- Trial name
- NCT01047319
- Testing
- Laquinimod
- Where
- 144 sites in United States, Bulgaria and 16 more
- Volunteers
- 1,047 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or…
- Trial name
- OMS115102 (NCT00640328)
- Testing
- Ofatumumab 100, Ofatumumab 300, Ofatumumab 700
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis
The purpose of this study is to compare two different educational programs for people with multiple sclerosis (MS), which is a common and often disabling disease of the central nervous system.
- Trial name
- NCT01918800
- Testing
- Fatigue: Take control, MS: Take Control
- Where
- 4 sites in United States
- Volunteers
- 282 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Healthy Adult
Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis
The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)
- Trial name
- GAIT-MS (NCT07388992)
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SYSNAV
Multiple Sclerosis, Balance
Spinal Alignment, Spinal Mobility, and Balance in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system characterized by demyelination and axonal degeneration.
- Trial name
- NCT07648277
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ankara Yildirim Beyazıt University
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Multiple Sclerosis, Healthy Controls
Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy
Multiple Sclerosis (MS) is the most common chronic inflammatory neurological disorder in young adults. Due to heterogeneous symptoms, MS patients are often more inactive than healthy controls, resulting in an inactivity related…
- Trial name
- NCT02466165
- Testing
- Physical exercise
- Where
- 2 sites in Belgium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bert Op't Eijnde
Multiple Sclerosis, Relapsing-Remitting
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone.
- Trial name
- REMAIN (NCT01142466)
- Testing
- Interferon beta-1a (Rebif)
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01144351
- Testing
- ELND002
- Where
- 20 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis
Vitamine D in Multiple Sclerosis
Two hundred and forty patients with multiple sclerosis who met the study criteria will be enrolled in this randomized double blind placebo-controlled clinical trial.
- Trial name
- MSVit (NCT01768039)
- Testing
- Vitamin D
- Where
- Iran
- Volunteers
- 240 people
- Sponsor
- Mazandaran University of Medical Sciences
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
- Trial name
- NCT03737812
- Testing
- elezanumab
- Where
- 37 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- AbbVie
Multiple Sclerosis
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The primary objective of Part A is to determine the safety and tolerability of natalizumab administered over 24 weeks in Japanese participants with relapsing-remitting multiple sclerosis (MS).
- Trial name
- Tysabri Japan (NCT01440101)
- Testing
- Natalizumab (BG00002)
- Where
- 17 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Biogen
Back Pain, Coronary Artery Disease
Detecting and Addressing Preclinical Disability
The Physical Functioning Inventory (PFI) is a standardized patient reported outcome measure that assesses preclinical disability.
- Conditions
- Back Pain, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Diabetes
- Trial name
- NCT01979081
- Testing
- Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- McMaster University
Tuberous Sclerosis Complex
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Tuberous Sclerosis is a rare genetic disorder that affects about one in 15,000 individuals. It is part of the phacomatoses: a germline mutation of the gene Tuberous Sclerosis Complex 1 (TSC1) or TSC2 causes a protein dysfunction…
- Trial name
- NCT04112537
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
The aim of this case series was to document the effectiveness and compatibility of Rebif 44 or 22 µg in the therapy of the chronic multiple sclerosis (MS) under practical conditions on a large collection of subjects.
- Trial name
- NCT01142557
- Testing
- Interferon beta-1a (Rebif)
- Where
- Germany
- Volunteers
- 522 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis
1. To determine the safety and tolerability of oral Cellcept when used in combination with weekly intramuscular Avonex in early MS. 2. To document changes in exacerbation frequency, 3.
- Trial name
- NCT00223301
- Testing
- Mycophenolate Mofetil (cellcept)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.